On February 4, 2022 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported that company management will participate in the following upcoming investor conferences (Press release, Asher Biotherapeutics, FEB 4, 2022, View Source [SID1234607762]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th Annual Guggenheim Oncology Conference
Craig Gibbs, Ph.D., will present a corporate overview on Friday, February 11, 2022 at 1:00 p.m. ET (10:00 a.m. PT). Company management will also participate in 1×1 meetings on Friday, February 11, 2022.

SVB Leerink 11th Annual Global Healthcare Conference
Company management will participate in 1×1 meetings on Monday, February 14 and Tuesday, February 15, 2022.

On February 4, 2022 FibroGen, Inc. (NASDAQ: FGEN) reported that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST (Press release, FibroGen, FEB 4, 2022, View Source [SID1234607761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio webcast of the event will be available on the "Events & Presentations" section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

On February 4, 2022 FibroGen, Inc. (NASDAQ: FGEN) reported that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST (Press release, FibroGen, FEB 4, 2022, View Source [SID1234607760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio webcast of the event will be available on the "Events & Presentations" section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

On February 4, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that its President and Chief Executive Officer, Robert E. Hoffman will present a corporate overview at the BIO CEO & Investor Conference, which is being held on February 14 – 17, 2022 at the New York Marriott Marquis in New York City, NY (Press release, Kintara Therapeutics, FEB 4, 2022, View Source [SID1234607759]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Hoffman will deliver his corporate presentation on Tuesday, February 15, 2022 at 2:00 p.m. EST.

Mr. Hoffman will be available for one-on-one meetings throughout the conference in person and virtually.

Additional information about the presentation can be accessed by visiting View Source

On February 4, 2022 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Oncology Conference 2022 on Feb. 9, 2022, at 2:30 p.m. EST (Press release, Merck & Co, FEB 4, 2022, View Source [SID1234607758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source and-presentations/.